We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go: Expired investment: £5,877,517
Go Modular design and build off-site modules for the construction industry. Using their innovative modular construction technology they aim to revolutionise the construction process making it more time efficient and less expensive to produce buildings. In 2018, Go Modular are looking to open their first factory in the UK which will enable them to offer the construction industry factory-produced building units that form the finished structure at the construction site.
days to go: Expired investment: £412,420
Bioepic is an app which enables users to easily and non-invasively measure their health status in just 30 seconds using just a smartphone. The app calculates pulse wave velocity, body temperature, blood pressure, heart rate variability chaos, vascular stiffness and the effectiveness of inhalers. 
days to go: Expired investment: £12,500
Artfinder is the art world's first certified B corporation that is on a mission to create a world where art benefits everyone. Operating in the $55 billion+ wall décor and online art market, the company is backed by Wellington Partners, and private investors in the UK, US and Switzerland. It has 60,000 customers, 6,000 artists and a collection of 470,000 artworks. The company believes in establishing direct contact with artists to select or commission work and negotiate prices. Customers have rated the company highly with 4.8+ Trustpilot reviews. The company will use the investment to supercharge its growth, grow its team and improve its platform.

Pitch Rated

85%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £834,056
Creative Hub is a fast-growing cloud software platform for creative people to store, share files, and collaborate on projects. The collaboration tools also allow users to chat in real-time, and add comments on images, allowing creative teams to work faster and deliver better results. Creative Hub enables users to order professional art & photographic prints, or physical 3D prints, which are produced at its print production facilities in London(UK) and Dusseldorf (Germany). The platform currently has 40,000 active users which are growing day by day. With the investment, the company will drive growth through marketing and launch its New York production facility.

Pitch Rated

76%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £286,992
Vegums develop multivitamin gummies for a vegan and plant-based lifestyle. The company argues that some vitamins are difficult to get from a plant-only diet, such as vitamin D, B12, and iodine. Vegums has researched and incorporated non-animal vitamin ingredients into its products to address that issue. The company asserts that its products are 100% plastic-free and biodegradable. It claims that the number of vegans in the UK grew by 40% in 2020, and shows no sign of slowing down in 2021. It aims to become a contender in this segment. Vegums won the World Plant Award 2020 for the 'Best Plant-Based Start-Up', has a social media following of over 15,700 on Instagram, achieved 4.8/5 on TrustPilot, and scaled from selling 1 pack of Vegums to over 9,000 a month to its customers. It will use the investment for New Product Development (NPD), team expansion, and launching into new markets and countries.
days to go: Expired investment: £312,463
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph